Regenxbio Inc
NASDAQ:RGNX
| Market Cap (Intraday) | 447.08M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.77 |
| 50-Day MA | $8.55 |
| 200-Day MA | $8.26 |
Regenxbio Inc Stock, NASDAQ:RGNX
9804 Medical Center Drive, Suite 210, Rockville, Maryland 20850
United States of America
Phone: +1.240.552.8181
Number of Employees: 353
Description
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.